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Summary 
We have investigated four secretion-deficient antibodies (Abs) derived from a panel of 46 mutant 
T15 anti-phosphocholine  Abs, all of which have point mutations in the heavy chain (H) com- 
plementarity determining region 2 (CDK2). The level of secretion for these four Abs was <10% 
of  wild type when expressed  together with the T15 light chain (L) in either SP2/0 or P3X63Ag8.653 
myeloma cells although normal levels of H and L chain mRNA were produced. Moreover, abundant 
intracellular H and L chain proteins were detected. Three of the four mutants had little or no 
assembled H and L complexes intracellularly whereas one had a significant amount of intraceUular 
immunoglobulin (Ig) which was shown to be capable of binding Ag. Thus, we demonstrate 
for the first time that point mutations confined to CDK2 of the H  chain variable (V) region 
can impede Ab assembly and secretion. We then introduced the same CDK2 mutations into 
a related H  chain which is encoded by the same T15 VH gene but different diversity (D) and 
joining (J) genes. When these H chains were expressed with a non-T15 L chain, the resulting 
Abs were secreted normally. The results thus suggest that the effects of the CDK2 mutations 
on Ab secretion are dependent on their interactions with L and/or H chain D-J sequences. These 
results also reveal a novel mechanism that could contribute to B cell wastage. 
T 
he process of somatic mutation appears to operate ran- 
domly throughout Ab V regions, however, because of 
the selective force of Ag,  specific mutations that confer a 
binding advantage to the B cell become dominant and thus 
provide a biased view of the structural consequences of so- 
matic mutations. Mutations that fail to improve Ag binding 
are less well understood since such Abs are not easily recov- 
ered, however, this is the category of mutation that is likely 
to contribute to B cell  wastage during an Ag-driven response. 
We have chosen to analyze the structural consequences of 
V region mutations that result in loss of Ab function. Be- 
cause formation of a functional Ab molecule is a complex, 
multi-step process, a number of mechanisms could contribute 
to loss of  function, including those affecting interactions with 
Ag, protein assembly, and Ab secretion. 
The pathways of Ig assembly were delineated in classic 
studies by Scharff and his colleagues (1, 2) who showed that 
the assembly of H  and L chains of each isotype followed a 
major and a minor pathway. For IgG2b, the major pathway 
was H+L-~HL--*H2L2.  The minor pathway consisted of 
H+L-*HL"-*HL+H-'*H2L+L--*H2L2.  The structure of the 
H  chain isotype appeared to determine the pathway of as- 
sembly since most of the tumor cells studied utilized K  chains 
(1). Furthermore, it has been suggested based on H + L chain 
reassociations in vitro, somatically mutated H chains may be 
more restricted in their ability to pair with heterologous L 
chains than unmutated H chains (3). Thus, mutations in ei- 
ther chain that affect assembly have the potential to prevent 
proper transport and secretion. 
Studies of faulty Ab assembly and secretion have revealed 
several abnormal Ig products: secreted L chain monomers and 
dimers (4), secreted mutant H chains (5, 6), and secreted par- 
tially folded Ig (7). In most of these mutants the nonsecreted 
Ab is retained in the endoplasmic reticulum (EK)  1 (8). Free 
unmutated L chains can be secreted in the absence of H chains 
(9, 10), but free unmutated H chains are retained in the cell 
in the absence  of L chain (11, 12). Mutant L chains that cannot 
be secreted have been found in the lumen of the ER (10, 13). 
Mutations at Gly 15 in V~,2 (14) and Phe 62 in VM (15) 
have been shown to block secretion.  Phe 62~Ser blocked 
transport of M  from ER to the Golgi and prevented secre- 
tion even in the presence of H chain. The mutation at res- 
idue 62 did not cause gross misfolding since the mutants con- 
tained intracellular IgM that could bind Ag. More recently, 
1 Abbreviations used in this paper: EK, endoplasmic reticulum; PC, phos- 
phocholine; WT, wild type. 
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K chain caused the latter's retention in the ER (16). Most 
L chains contain Tyr or Phe at position 87,  and changing 
His 87 to Phe in VK21 restored secretion. 
The location of these L chain mutations led to the pro- 
posal that VL contains information essential for Ig secretion 
(15) in accord with earlier reports that transfected L chains 
can restore Ig secretion in ceils expressing only H  chains 
(17-19).  It is interesting to note that defective secretion of 
the MOPC21 x chain (containing His 87) can be "repaired" 
by coexpression  with H chain (16) as can defective secretion 
of another L chain, CH12K (20). Thus, some L chain secre- 
tion failures can be overridden by H chain. It was suggested 
that VH-VL assembly masks the negative influence of His 
87, thereby allowing the protein to continue on the normal 
transport pathway. However, the molecular nature of the in- 
teraction is unclear,  and it is important here not to rule out 
the possibility of a positive transport signal  resident on H 
chains,  as has been suggested previously (7). 
Analysis of the H chain contribution to Ig assembly and 
secretion has focused on two domains of the constant region: 
CH1 and the #s tailpiece. L chain-negative cell lines can se- 
crete  3/H chains in which CH1 is absent (7,  21,  22) and 
camds normally secrete IgG2 and IgG3 H chain dimers lacking 
CH1 and L chains (23).  However in order for free ~ chains 
to be secreted,  it appears that CH1 must be deleted and a 
site (Cys 575) in the #s tailpiece must be modified (6). These 
studies  suggest that retention sites in the H  chain constant 
region may be masked by L chain association or by polymer- 
ization into IgM pentamers before Ig transport proceeds. 
We show here for the first time that mutations in the VH 
CDK2 region can also result in loss of Ab secretion. We have 
created four mutants of the anti-phosphocholine Ab, T15, 
that only differ by two to four point mutations in the VH 
CDK2 yet their secretion is <10% of wild type (WT). This 
is the first evidence that the VH hypervariable region may 
be involved in the process of Ab secretion.  In addition, these 
results reveal a novel mechanism through which somatic mu- 
tation could contribute to the process  of B cell wastage. 
Materials and Methods 
Genoraic Cloning of DI6 VII Genes.  Genomic DNA obtained 
from D16 hybridoma cells was partially digested with EcoRI and 
ligated to )~ phage EMBL4 EcoRI arms (Stratagene, La  Jolla, CA). 
Approximately 106 phage recombinants were screened with JH- 
and VHl-specific  probes (24). A done positive for both probes was 
isolated and characterized  by restriction enzyme analysis. The 7.1- 
kb EcoRI fragment containing the productive V.1-D.SP2.2-J.2 
rearrangement of D16 was subcloned into the pTZ18U phagemid 
(Bio-Rad Laboratories,  Richmond, CA) for sequencing and subse- 
quent genetic manipulation. 
Plasmid Constructs.  The CDR2 of the germline $107 VH1 gene 
was randomly mutated as described previously (25) and the WT 
and mutated T15 VH fragments were cloned into the pSV2gpt 
vector provided  by Dr. J. Sharon (Boston University, Boston, MA) 
which contains the 3"2b C region gene (26). The pSV2neoVK22CK 
plasmid, a gift from Dr. S. Morrison (University of California at 
Los Angeles, Los Angeles, CA), was described  elsewhere (27). The 
germline CDR2 sequence of  the D16 VH1 gene was replaced  with 
mutated VH1 CDR2 sequences from the T15 mutants generated 
previously (25) using SmaI and XhoI digestion and subsequent li- 
gation into pTZ18U. The CDR2-rephced D16 VH genes were then 
subdoned into the pSV2gpt 3'210 plasmid. The VH1 sequences and 
the CDR2 mutations were verified  by sequencing  in both pTZ18U 
and pSV2gpt vectors using primers for VH1 framework 3 (25) and 
JH2 (24). 
Celt Culture and Transfection.  Cells  were cultured in IMDM 
(GIBCO BRL, Gaithersburg,  MD) containing t-glutamine, nones- 
sential amino acids, sodium pyruvate, and 15% FCS. Mutant and 
WT T15 cell lines were described previously (25). The D16 hy- 
bridoma was produced and characterized in this laboratory by Dr. 
M. Stenzel-Poore. It was derived from an early secondary  response 
to phosphocholine (PC)-KLH, in which a mouse received a pri- 
mary injection of 100/zg PC-KLH in CFA and was boosted on 
day 14 with 100/~g PC-KLH in IFA. Spleen cells were fused with 
the myeloma  cell line FO as described (28). D16 produces an IgM, 
VKlc,  group  II  anti-PC-protein  Ab.  Accordingly, it  binds 
nitrophenylphosphocholine much better than PC, is T15 id- and 
does not bind to PC-polysaccharide (29). D16 is encoded by the 
S107 VH1 germline sequence and thus is identical to T15 in this 
respect. It differs  from T15 in DJ and VK. An H chain loss variant 
of D16 was isolated by soft agar cloning (30) using a mouse em- 
bryonic fibroblast feeder layer (C3H/IOT1/2, kindly provided by 
Dr. M. Wilkinson (Oregon Health Sciences University). 
SP2/0 myeloma,  P3X63AgS.653 myeloma,  and H chain-loss  D16 
hybridoma  cells  were used as recipients  for DNA transfection.  Trans- 
fection was performed by the lipofectin method as described previ- 
ously (25) except that 100/~1 lipofectin and a 22-h incubation was 
used in each transfection in the case of D16 cells. In this study, 
the  SP2/0  cells were first transfected with a pSV2neoVK22CK 
plasmid and a stable VK22CK transfectant was then used as the re- 
cipient for subsequent transfection with WT or mutant VHS107- 
"y2b. In the case of  P3X63Ag8.653 cells, cotransfection of VK22CK 
and VHS107-'y2b was performed. 
ELISA.  The basic procedures of ELISA were described previ- 
ously (31). Antibody concentration was determined by sandwich 
ELISA in  which  microtiter  plates were coated with  rabbit 
anti-mouse "y2b (Zymed Laboratories Inc., South San Francisco, 
CA) or with goat anti-mouse K  (Southern  Biotechnology  Associates, 
Birmingham, AL). Serial dilutions of culture supernatant or cell 
lysate were added to the plates and alkaline phosphatase--labeled 
rabbit anti-mouse ~,2b or goat anti-mouse K  were used to detect 
the Ab. Purified Ab from hybridoma PCG2b-2 (3'2b, K) was used 
to generate standard curves. For T15 idiotypic expression, three 
anti-idiotype reagents were used. The mAb B36-82 (32) and the 
goat anti-T15 antiserum are specific for T15 VH and VL regions 
and were described previously (25). The mAb TC54 was a kind 
gift from Dr. M. Scharff (Albert Einstein College of Medicine, 
Bronx, NY) and is specific for the S107 VH region (33). Purified 
anti-idiotypic Ab was coated on the plates and then overlaid with 
protein A-Sepharose-purified mutant Ab at 100 ng/ml. Binding 
was  detected with  alkaline phosphatase-labeled rabbit anti- 
mouse 3'2b. 
Preparation of Celt Lysates.  Cell tysates  were prepared according 
to George et al. (34). Briefly,  cell pellets were lysed  in ice cold PBS 
containing 25 mM iodoacetamide, 20/zg/ml soybean trypsin in- 
hibitor, 50/~g/ml PMSF, and 0.25% NP-40 (all from Sigma Chem- 
ical Co., St. Louis, MO). Lysates  were incubated for 30 min at 
4~  before spinning out nuclei and insolubles. For ELISA, cells 
were plated in duplicate 4-ml cultures at 2  x  106 cells/ml, in- 
cubated for 4 h at 37~  washed twice in culture medium without 
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solution and assayed immediately. For Western blotting, confluent 
25 cm  3 flasks of cells were lysed in a volume of lysing solution to 
give an equivalent of 2  x  10  s cells/ml. 
Western Blot Analysis.  Cell lysates  were run on a  12%  SDS- 
PAGE gel under reducing conditions. The separated proteins were 
then electrophoretically transferred to an Immobilon P membrane 
(Millipore, Marlborough,  MA). The blot was blocked overnight 
at 4~  in PBSA (PBS with 0.02% sodium azide) containing 3% 
nonfat dry milk (NFDM).  The blot was incubated for 1.5 h  at 
room temperature in rabbit anti-mouse IgG2b (Zymed) diluted 
to 1/~g/ml in PBSA with 1% NFDM. After three 15-min washes 
in PBSA with 0.05% Tween-20, the blot was incubated in 0.5/zg/ml 
protein A-alkaline phosphatase conjugate (Sigma Chemical Co.) 
for 1 h. After washing as above, the blot was incubated 5 min in 
AMPPD chemiluminescent substrate from the Immuno-Lite Sub- 
strate Kit (BioRad), wrapped in Saran wrap, and exposed to film. 
Northern Analysis.  Cytoplasmic RNA was isolated by a mini- 
prep method (35). Northern blot was performed as described (36). 
Briefly, 10/~g RNA was loaded on 0.7% agarose gel and was elec- 
trophoresed for 4-7 h. RNA was then transferred to Nytran mem- 
branes which were hybridized with probes for VHS107 (37), VK22 
(38), and for the housekeeping gene CHO-A (39) which was kindly 
provided by Dr. M.  Wilkinson.  Autoradiographs were analyzed 
by  densitometric  scanning  using  a  densitometer  (model  620; 
Bio-Rad). 
Results 
Identification of Secretion-defective Abs.  We previously es- 
tablished a panel of T15 Abs restricted to random point mu- 
tations in VH CDR2 ($107) to study the effects of V region 
mutation on Ab function (25). In the course of making trans- 
fectomas with the mutated H  chain gene constructs, we found 
that  five mutants  yielded  clones  severely impaired  in  their 
ability to secrete Ab.  As shown in Table 1, mutants M102, 
M153, M164, M166,  and M241 had been transfected several 
times into an SP2/0 line containing the VK22 L chain gene. 
Of a  total of 331  mycophenolic acid resistant  clones,  only 
19 (6%) produced any level of detectable Ab, and, as described 
below,  this  level was extremely low.  In contrast,  transfec- 
tants containing WT or other H  chains with different CDR2 
mutations (M85, M171, and M154) yielded 51 out of 95 (54%) 
clones  that  secreted  normal levels of Ab. 
To determine if other mutations beyond the V region (we 
had sequenced the V  regions of all mutants before transfer- 
Table  1.  Identification  of 8107 Low Secretor Mutant Cell Lines 
Expt.  1  Expt.  2  Expt.  3  P3X63Ag8.653 
mpa  R  Ig +  mpa  a  Ig §  mpa  g  Ig §  mpa  a  Ig + 
Normal secretors 
WT  6"  2'  23  8  ND  ND  33  8 
M85  5  3  8  5  ND  ND  ND  ND 
M171  5  3  12  6  ND  ND  ND  ND 
M154  22  17  14  7  ND  ND  ND  ND 
A61T  ND  ND  ND  ND  ND  ND  29  18 
Total  38  25  57  26  62  26 
Low secretors 
M102  13  -  47  -  ND  ND  ND  ND 
M153  22  1,  2s  5  -  32  2,  2s  45  lS 
M164  13  2 s  ND  40  2s  55  4s 
M166  18  2 s  33  3 s  17  -  24  2s 
M241  27  1  s  ND  ND  64  2s  19  - 
Total  93  8  85  3  153  8  143  7 
WT and VHCDR2 mutated T15 transfectants were generated as described in Materials and Methods. Each experiment represents a separate transfec- 
tion. SP2/0-Vg22 cells were the recipient cells in experiments 1-3 whereas in the last experiment P3X63AgS.653 cells were transfected with VHS107 
together  with V~22. 
* mpa  R is the number of mycophenolic acid resistant clones (which indicates the presence of transfected H chain DNA) compared to the number 
of normal antibody secreting clones (Ig  +) obtained in each transfection. 
* Ig + antibody secretion was determined by direct binding ELISA as indicated in Materials and Methods. 
S Transfectants had an OD4os reading <0.3  at a time point  when  WT readings were/>1.0.  (-) Undetectable. 
579  Chen et al. tion)  were affecting Ig expression,  up to 500 bp of the  5' 
flank were sequenced.  Only M102 had an altered  5' flank, 
a deletion of 200 bp that is probably responsible for the non- 
secretor phenotype, and further studies on this mutant were 
not performed. In contrast, the only differences distinguishing 
the other four low secretor mutants from the WT and the 
normally secreting mutants are the particular CDR2 muta- 
tions  shown in Fig.  1. 
Since the  same SP2/0 cell line and the  same procedures 
were used for all transfections, the reproducibility of the low 
secretor phenotype suggested a defect intrinsic  to the mu- 
tated H  chains. Nevertheless, in order to rule out a possible 
contribution by the transfection recipient, SP2/0, we made 
additional transfectants of the four low secretor H chain genes 
(excluding M102 from further  analysis)  and the WT $107 
H  chain  gene together  with  the VK22-CK  gene using  an- 
other myeloma line as recipient, P3X63AgS.653.  As shown 
in Table  1,  the low secretor phenotype was also exhibited 
in this cell line as only 7 of 143 drug-resistant  clones con- 
raining  the low secretor H chains produced any detectable Ab. 
Ig and mRNA Levels of  Low Secretor  Mutant Cells.  Clones 
that  exhibited Ig levels  above background  during  the first 
screen were saved from each mutant  (a few negative clones 
were also saved). The amount of Ab secreted was quantified. 
As shown in Table 2,  after 4 d of culture,  the low secretor 
clones had very low levels of Ig in the supernatants,  ranging 
from undetectable to 6.8% of the WT transfectant. Further, 
in other  experiments  using biosynthetic labeling,  Ig H2L2 
complexes were detected by 6 h in WT supernatants but not 
in low secretor supernatants  (data not  shown).  Ig was de- 
tectable by ELISA in the supernatants of low secretor clones 
only after several days of culture and the amount was inversely 
NORMAL  SECRETORS 
50  51  52  a  b  c  53  54  55  56  57  58  59  60  61  62  63  64  65  Ig 
WT  A  S  R  N  K  A  N  D  Y  T  T  E  Y  S  A  S  V  K  G  + 
M85  -  -  I  .....  H  ..........  + 
M107  ..............  G  ....  + 
M154  -  o  -  K  .....  I  .........  + 
M171  -  -  G  T  ...............  + 
A61T  ..............  T  ....  + 
M102 ~  .......  Y  -  A  P  Q  -  -  -  T  -  - 
M153  .............  T  V  -  M  T  -  • 
M164  I  .........  S  ......  • 
M]66  -  -  K  .......  G  -  -  -  Y  M  -  :l: 
M241  R  .....  E  ....  S  ......  • 
Figure  1.  Amino acid sequences of VHS107 CDR2 WT and mutant 
H chains of normal secretor and low secretor transfectant clones. The re- 
mainder of the H and L chain sequences are identical to WT T15.  (lg +) 
normal secretion; (Ig+_) secretes  <10%  of WT;  (Ig-)  no Ig detected. 
Status defined quantitatively in Table 2. M102 was unable to produce any 
Ig presumably because of a 200-bp deletion in the 5' flanking region as 
discussed in the text. These sequence data are available from EMBL/Gen- 
Bank/DDBJ under accession  number X79818. 
Figure  2.  H chain mRNA levels of low secretor clones. Autoradiograms 
of Northern blots for WT and some of the low secretor clones are shown. 
RNA samples  were first probed for VHS107 (top) and the membranes 
stripped and reprobed for CHO-A (bottom) as described  in Materials and 
Methods. Clone names are indicated above each lane. 
proportional  to cell viability.  Thus it is possible that  some 
or all of the mutant  clones are  true  nonsecretors  and  that 
Ab is only detectable in the supernatants  after cells begin dying. 
However, since this point has not been formally established, 
we use the  term  low secretor to describe the phenotype. 
To determine if the defect in Ig secretion is at  the tran- 
scriptional level,  the levels of H  and L chain mRNA were 
examined.  Northern  analysis  with  the 5107 VH probe re- 
vealed that the H  chain mRNA levels of most low secretor 
clones were comparable to or higher than the WT clone (Table 
2 and Fig. 2). Moreover, the sizes of the H  chain transcripts 
in the WT and the mutant clones were the same, indicating 
that gross deletions or truncations were not present. Northern 
analysis using a VK22 probe also indicated that  most trans- 
fectants had normal levels of L chain mRNA (Table 2). Clearly, 
transfection had been successful in most instances,  suggesting 
the basis for failure to secrete Ig at normal levels is located 
at  some point  after transcription. 
Binding Analysis of the Antibody.  Anti-idiotype reagents 
were used to determine whether gross conformational changes 
or misfolding might be present in the mutant Abs. The mu- 
tant clones were grown for several days to allow Ab to ac- 
cumulate in the supernatant.  Antibodies were purified from 
the  supernatants  of clones M153-1,  M164-4,  M166-1,  and 
M241-2. Three different anti-idiotype reagents were used to 
test for conformational changes that might disrupt recogni- 
tion by the anti-idiotype. TC54 is a mAb specific for the $107 
VH gene product present  in T15 even in the absence of L 
chain (33). The mAb B36-82 and the polydonal antiserum 
recognize T15 idiotopes requiring the presence of both T15 
VH and Vg22 (25). All four low secretor mutant Abs were 
recognized by B36-82 and by the anti-T15  antiserum,  indi- 
cating  that  the epitope formed through  the interaction  of 
H  and L chains was essentially intact  (Table 3).  M153 and 
M166 also bound to TC54 (although with reduced avidity) 
whereas binding to M164 was not detected. It appears that 
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Antibody secreted  Ig mRNA 
Mutants  ng/ml  Percent  WT  VHS107  VK22 
WT SP2/0*  736~  100  1.0 s  1.0 
WT P3X63Ag"  296  100  1.0  1.0 
M153-1  2.8  0.4  8.54  11.8 
M153-5  -  2.88  0 
M153-6  2.6  0.4  2.92  6.97 
M153-7  2.7  0.4  0.40  ND 
M153  P3X63Ag"  -  0.51  0.16 
M164-1  -  0.28  0 
M164-2  -  1.57  0.58 
M164-3  2.0  0.3  1.42  0.11 
M164-4  12.7  1.7  0.26  2.03 
M164  P3X63Ag"  7.5  2.8  2.29  3.05 
M166-1  15.6  2.1  3.08  2.85 
M166-2  28.0  3.8  6.58  2.75 
M166-3  8.3  1.1  2.18  3.41 
M166o4  50.0  6.8  5.70  2.79 
M166o5  4.8  0.7  2.08  3.48 
M166-6  -  1.25  0.79 
M166  P3X63Ag II  7.2  2.7  14.02  5.65 
M241-1  -  3.72  0.72 
M241-2  2.6  0.4  1.29  0.81 
M241-3  -  2.13  1.07 
M241-4  -  0  0.57 
M241  P3X63Ag"  -  0.36  0.93 
* Each clone of the mutants  was independently isolated (represents an independent transfection event of the designated mutant  H chain). 
* The same number of cells (10  s) was plated for each clone and the supernatants were collected on day 4. Antibody was quantitated on anti-IgG-coated 
plates using purified isotype-matched antibody as standard.  (-) <0.1  ng/ml. 
S mRNA was determined by Northern  analysis using VH $107 or Vx22 specific probes. The relative amount of mRNA was estimated by densitom- 
etry scanning and normalized to the mRNA signal from the CHO-A housekeeping gene. 
If Clones are from P3X63Ag8.653  transfectants. 
the epitope recognized by TC54 is vulnerable to alterations 
caused by CDR2 mutations since the normally secreting mu- 
tant, M85, has also lost this epitope. This is consistent with 
an earlier report that a mutant $107 molecule bearing six VH 
mutations,  one of which  was in  the  CDR2,  had  also lost 
its ability to bind to TC54 (40) and with our own findings 
that other residues in this region may also affect the TC54 
epitope (Chen, C., V. A. Roberts, S. Stevens, M. P. Stenzel- 
Poore and  M.  B.  Rittenberg,  manuscript  in preparation). 
The integrity of the Abs was also tested by their ability 
to bind to the Ag,  PC-histone.  Although,  as shown previ- 
ously, mutations in VH CDR2  of T15 frequently result in 
loss of Ag binding (25),  the low secretor M153 Ab isolated 
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from cell lysates was able to bind PC-protein.  These data in- 
dicate that the mutated H  chains are unlikely to be grossly 
misfolded,  and in the case of M153,  can combine with the 
L  chain  to form an intact Ab or an L/H dimer.  However, 
the above experiments do not indicate whether the mutated 
H  chains in the low secretors have a normal efficiency or pat- 
tern  of pairing  with  the  L  chain. 
Examination of  lntracellular lg Proteins.  To determine if the 
mutant H  chain proteins accumulate in the cells and if they 
assemble with the L chain efficiently, we employed an ELISA 
to detect intraceUular  Ig in cell lysates.  One representative 
clone of each low secretor mutant (M153-6, M164-3, M166- 
3,  and M241-2)  was analyzed and  compared to WT.  Cells Table  3.  Binding Features ofS107 Low Secretor Mutant Ig as 
an Indication of Conformational Changes 
Anti-T15  id 
TC54  B36-82  antiserum  PC-his 
WT  +++  +++  +++  +++ 
M85  -  +  +  +  +  +  +  - 
M171  +  +  +  +  +  +  +  - 
M154  +  +  +  +  +  +  +  +  - 
M153  ++  +++  +++  ++ 
M164  -  +  +  +  +  +  +  - 
M166  +  +  +  +  +  +  +  - 
M241  ND  +  +  +  +  +  +  - 
Binding to various anti-T15 antibodies and to PC-histone was determined 
by direct binding ELISA as described in Material and Methods. Affinity- 
purified antibody was used in anti-idiotype analysis (the low secretor clones 
M153,  M164,  M166,  and M241 were cultured for an extended period 
of time in order to accumulate sufficient Ig in the supernatant for test- 
ing). Either lysates (M153, M164, M166, and M241) or affinity-purified 
antibody (M85, M171, and M154) were used in PC-histone binding as- 
says.  WT  antibody had high OD  readings in the PC-histone binding 
assay regardless of whether it was affinity purified or from lysate. Anti- 
bodies were added to the anti-T15 or PC-histone coated plates at a con- 
centration  of  100  ng/ml.  The  OD  readings  of triplicate  wells  were 
averaged  and are expressed  in a  simplified scale:  +  +  +  (>0.8);  +  + 
(0.2-0.8);  +  (0.01-0.2;  -  (<0.01).  The mutant clones M85,  M171, 
and M154 secrete Ig which is not able to bind antigen as described previ- 
ously (25). 
were cultured for 4 h and Ig proteins in the lysates and super- 
natants were quantified by ELISA. As shown in Table 4, all 
four mutant clones had a large amount of H  chain protein 
in the cells, ranging from 68 to 185% of the WT level. How- 
ever, the intracellular H/L dimers (or tetramers) were greatly 
reduced in the mutants. Clones M164, M166, and M241 had 
only 1-8%  of the WT level of assembled protein. The ex- 
ception is M153, which contained intracellular H/L protein 
at 36%  of WT level in keeping with our ability to detect 
Ag binding activity in this extract. 
By 4 h of incubation, the WT clone already had secreted 
a significant amount of Ab into the supernatant (Table 4). 
However, at this time point,  little or no Ab could be de- 
tected in the supernatants of the mutant clones, including 
M153.  Thus,  in addition to reduced assembly,  a defect in 
transport/secretion may also  account for the low secretor 
phenotype. 
In addition to the ELISA analysis described above, intra- 
cellular H and L chains were visualized by Western blot (Fig. 
3). The proteins in cell lysates were separated by SDS-PAGE 
under reducing conditions and H and L chains were detected 
with anti-'r2b Abs (which fortuitously cross-react with L 
chains). H  and L proteins were seen in all four low secretor 
lysates, as well as WT lysates. These proteins run at apparent 
molecular mass of 54 (H chains) and 26 kD (L chains), and 
both migrate very similarly to purified MOPC 195 proteins 
(3'2b, K), indicating that no gross alterations of the protein 
have occurred. Together, these data suggest that the impaired 
Ab secretion in these mutants is not due to defects in protein 
synthesis. Rather, deficient H/L assembly or stability may 
be a major reason for the low secretor phenotype of these 
mutants. The exception is M153 which appears to assemble 
but fails to  secrete the mutant molecules (consistent with 
higher levels of intracellular H  and L proteins compared to 
WT in Fig.  3). 
Effect  of Different L  and H  Chain  D-J Sequences  on Secre- 
tion.  In an  attempt  to  investigate  whether  the  same  set of 
T15 CDR2 mutations would have similar effects on Ab func- 
tion when associated with a different Ab, the mutated CDR2s 
were placed in the VH of another mAb, D16, which is en- 
Table  4.  Quantitation  by ELISA  of Intracellular Ig Proteins in  WT and Mutant Clones 
Lysate  Supernatant 
H  H+L  H+L 
ng  %  ng  %  ng  % 
WT  16.31  100  9.24  100  31.02  100 
M153-6  30.17  185  3.34  36  0.03  0.1 
M241-2  16.71  102  0.51  5  - 
WT  16.67  100  15.70  100  35.35  100 
M164-3  12.40  74  1.29  8  - 
M166-3  11.35  68  0.13  1  - 
Cells were cultured for 4  h  before collection.  Cell lysates were prepared as described in Materials and Methods.  IntraceUular protein was detected 
by ELISA using either anti-',/2b (H) or anti-g (H + L) coated plates,  all of which were developed by an anti-IgG2b-alkaline phosphate conjugate. 
Total ng of Ig protein was determined using isotype-matched,  purified antibody as a standard.  The number of cells collected for lysis was used to 
calculate the amount of protein per million cells. Mutants M153,  M241 and mutants M164,  M166 were tested on separate days,  each with a WT 
control.  (-)  <0.01  ng per million cells. 
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chain levels of low secretor clones. 
SDS-PAGE of lysates and Western 
blotting with anti-mouse 3~2b as de- 
scribed in Materials and Methods. 
MOPC 195 (~/2b, K) is purified an- 
tibody from this hybridoma. SP2/0 
VK22  is  the  L  chain-containing 
transfectant used as the recipient of 
WT and mutant H chains. SL12.4 
and SP2/0 (untransfected) are nega- 
tive control lysates. SL12.4 is an im- 
mature murine T cell line provided 
by Dr.  Miles Wilkinson (Oregon 
Health  Sciences University).  The 
additional bands that migrate above 
the L chain present in SP2/O  VK22 
and M153-6 are seen in unreduced 
Western blots (not shown) and may 
indicate  that  reductions  of  the 
highly concentrated  lysates are not 
complete.  The low mol wt bands 
at the bottom of the blot represent 
nonspecitic detection.  Clone names 
are indicated above each lane, H and 
L chain bands  are labeled with an 
arrow, and mol wt markers are in- 
dicated  on the right. 
coded by the same germline $107 VH gene as T15 but differs 
from T15 in D-J and VL (Fig. 4). Unexpectedly, all four D16 
transfectants  with the low secretor CDR2 mutations secreted 
high levels of Ab, ranging from 59 to 141% of the WT level 
(Table  5). 
Thus,  the contribution  of the CDR2 mutations  to low 
secretion is complex and may be modified through interac- 
tion with VL and/or D-J. This result also emphasizes that 
the CDR2 mutations are unlikely to have caused major struc- 
tural  alterations  in  VH. 
Discussion 
In this study we have shown that point mutations in the 
H  chain CDK2 are the cause of defective secretion of an Ig. 
We drew this conclusion based on several observations. First, 
L chain-bearing cells transfected with the mutated H  chain 
genes secreted little Ab whereas cells receiving the same H 
chain gene without mutations  or with different mutations 
in CDK2 secreted normal amounts of Ab. Second, the low 
VH  DH  JH  VL 
TI5  S107  DYYGSS  YWYFEVWGAGTTVTVSS  V~:22 
DI6  $107  GHYD  YFEYWGQGTI'LTVSS  V~r -C 
Figure  4.  Comparison of T15 and D16 D-JH sequences; their VH se- 
quences are identical. Amino acid sequences are shown as single-letter code. 
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secretor phenomenon was observed in repeated transfections 
with the mutant H chains in two different cell lines and mul- 
tiple transfectants,  excluding the possibility that low secre- 
tion was caused by an error in transfection or a defect in the 
secretory apparatus of the cell itself. Third, no mutations other 
than those in VH CDK2 were present as determined by se- 
Table  5.  Effects of L  and H  Chain D-JH Replacement 
on Antibody Secretion 
Ig combination 
Antibody  secreted 
Percent 
VH  D-JH  VL  ng/ml  WT 
WT  $107  T15  VK22  736.0  100.0 
M153  T15  VK22  2.8  0.4 
M164  T15  VK22  12.7  1.7 
M166  T15  VK22  50.0  6.8 
M241  T15  VK22  2.6  0.4 
WT  $107  D16  VK1-C  642.0  100.0 
M153  D16  VK1-C  376.0  58.6 
M164  D16  VK1-C  904.0  140.8 
M166  D16  VK1-C  483.0  75.2 
M241  D16  VK1-C  381.0  59.3 
Quantitation  of secreted antibody was  done as in Table 2. quencing of the entire V gene. Fourth, transcription or sta- 
bility of the H  chain mRNA appears not to be affected by 
the mutations since the low secretor mutants express abun- 
dant H  chain mRNA.  Fifth, normal levels of H  chain pro- 
teins were detected intracellularly; thus the defect appears to 
be Posttranslational. 
Somatic hypermutation in Ab V regions represents an im- 
portant means of generating Ab diversity, in particular, im- 
proving Ab afl[inity after antigenic stimulation (41). Since mu- 
tations  are  introduced  randomly  into  the  V  region,  it  is 
predicted that many mutations would result in nonfunctional 
Ab such as the low secretors described here.  Based on the 
frequency of invariant residues in the frameworks it has been 
estimated that 50% of mutations in these regions would re- 
sult in nonfunctional Ab (42). However, previous efforts to 
identify such mutations in the VH region have been limited. 
For example, substitution of the invariant VH residue Cys- 
92-~Tyr or Trp-36-~Ala  did not  show any apparent  effect 
on Ab function (43, 44). Here we show that four mutant 
Abs with two to four mutations in the VH CDR2 are secre- 
tion deficient. These results were unexpected because muta- 
tions in the CDRs are usually thought to be permissive due 
to the highly variable nature of CDR sequences and their 
importance for generating diversity. These four mutants came 
from a pool of 46 Abs all of which have point mutations 
in VH CDR2.  Approximately 50% of these mutants had 
lost or displayed reduced binding to Ag (25).  Of the 46 mu- 
tant Abs originally described (25),  2 of 9 with four muta- 
tions and  1 of 10 with  three mutations  are shown here to 
be low secretors. Thus the secretion defect does not reflect 
the number of mutations but rather their location. The high 
frequency (4 of 46) of low secretion mutants caused by random 
CDR2 mutations emphasizes that extensive B cell wastage 
may occur during the process of somatic mutation and that 
the creation of nonsecretor variants,  in addition  to loss of 
Ag binding,  may be a significant factor leading to wastage. 
There is increasing evidence that the correct folding and 
assembly of secreted proteins  are necessary for their  trans- 
port and secretion (45). To determine if the low secretor H 
chains were misfolded, we tested their binding to several anti- 
idiotypic  Abs.  Two  of these  reagents  recognize  epitopes 
provided by the correct combination  of H  and L  chain V 
regions and the other recognizes structure provided by the 
H chain V region alone. All four low secretors appear to re- 
tain the T15 VH-VL epitope(s) whereas the TC54 VH epi- 
tope was lost in one of the three mutants tested. In addition, 
one of the low secretor Abs, M153, was able to bind Ag. 
Thus, the low secretor mutations in VH CDR2 do not ap- 
pear to cause a gross misfolding of the H chain although local 
conformations  such as  those recognized by TC54 may be 
altered. 
On the other hand,  the levels of intracellular  H-L dimer 
(or tetramer) in these low secretors were greatly reduced (three 
had <10% of the WT level) even though the amount of un- 
assembled H  chains was normal.  The L chain expression in 
these cells should not be an affecting factor since the same 
SP2/0 cell line (which contains a previously transfected VK22 
L chain gene) was used in all the transfections in this study 
and the L chain mRNA expression was normal in most clones 
of the low secretors. The finding that three mutants exhibit 
very little intracellular H-L protein could result from ineffldent 
pairing of the mutant H chain with the Vr,22 L chain. Precious 
in vitro experiments have suggested that some H  +  L pairing 
may be favored over others (46-48) and, as indicated above, 
may be affected by somatic mutations (3). Our data may there- 
fore suggest that  local  structural  alterations  caused by the 
CDR2 mutations  interfere with H-L assembly and/or the 
stability of the assembled proteins,  and may represent the major 
cause of the low secretor phenotype in  three  of the  four 
mutants. 
As shown above, mutant M153 makes a reasonable amount 
of Ab (36%  of WT level),  but it is not secreted.  Thus,  a 
defect in Ab transport/secretion appears likely. The prevailing 
view of Ab assembly and secretion is that  unassembled H 
chains are retained in the EK via their interaction with the 
chaperone BiP. BiP is displaced when free L chains become 
available, and the assembled Ab is transported along the secre- 
tory pathway based on signals provided by the L chains (15, 
49). Previous studies of X chain secretion demonstrated that 
a single substitution at position 15 (Gly-~Arg) of X2, or po- 
sition 62 (Phe-"Ser) of ~1 L chains, was sulticient to block 
secretion (14,  15).  Since both of these residues are located 
on the solvent-exposed surface and are close to each other 
as predicted by the McPC603 model, it has been proposed 
that they are included in a surface patch that is required for 
intracellular  Ig transport  (15).  Here we show for the first 
time that mutations in the H chain V region may also affect 
Ab transport.  How a local alteration in VH CDR2 could 
be involved in this process is not clear.  The alteration may 
destroy a transport signal or create a retention signal in VH. 
Or, it may block or alter the transport signal in the L chain 
through interactions at the L/H interface. This latter possi- 
bility is supported by our finding that  the same mutant H 
chains were secreted when transfected into a cell line (D16) 
expressing a different Vg gene. The relationship of the two 
L chains to the CDR2 mutations is not clear at present. Vg22 
alone is not able to be secreted (Scharff, M. D., personal com- 
munication  as cited in reference 19,  and confirmed in our 
transfectants).  In contrast,  we have found that  the D16 H 
chain loss variant secretes large amounts ofVKlc L chain (data 
not shown). The role played by WT H chain in the secretion 
of T15 Ab and the role of Vglc in rescue of secretion defec- 
tive mutant H chains remains to be determined.  Further in- 
vestigations on the intracellular transport of the mutant Abs 
in conjunction with their structural  analysis  should clarify 
these possibilities. 
It is generally recognized that it is the framework or con- 
served V region residues that provide the structural basis for 
proper Ig folding and assembly (50). In the V domain,  the 
CDRs loop out from the fl-pleated sheets of the framework 
regions and form the surface that interacts with Ag. Thus 
it is surprising to see the low seeretor phenotype associated 
with VH CDR2. Indeed, residues in VL regions known to 
affect secretion (10,  14-16), and V region positions impor- 
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conserved sites. However, even though there is extensive se- 
quence diversity in the CDK residues, the many known Ab 
structures actually fit into a small number of main chain ca- 
nonical structures in the hypervariable regions (50). This CDR 
structural constraint is believed to be important in forming 
an Ag binding site. Two of the low secretor  mutations de- 
scribed here occur in canonical residues 51 and 52, and sev- 
eral other low secretor mutations are found in a region (56-63) 
where all known Ab structures exhibit essentially the same 
main chain conformation (50) (Fig. 1). Thus it is intriguing 
to consider the possibility that canonical structures in the 
CDKs may also affect aspects of Igs not associated with Ag 
binding, such as assembly or intracellular transport. In addi- 
tion, residues 59 to 65 form the second loop of VH CDK2 
which is distant from the binding cavity but in proximity 
to the L chain framework 2 region in T15 (25).  VL frame- 
work 2 is important for formation of the VL-VH interface 
in McPC603  (51), thus substitutions in VH  CDK2 may 
change the conformation of this loop and interfere with or 
alter H-L assembly. 
Collectively, these low secretors contain amino acid replace- 
ments in two general regions of VH CDR2, 51-52 and 58- 
63, which could potentially perturb several aspects of assembly 
or transport of the Ig. However other mutants we described 
previously also had mutations at these same canonical posi- 
tions (but in different combinations) and yet were secreted 
normally (25).  Further investigation to examine the effects 
of individual and combined mutations by site-directed muta- 
genesis and detailed computer modding will help to clarify 
these issues and improve our understanding of the structural 
requirements for Ab assembly and secretion. 
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